BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC)

Historical Holders from Q1 2016 to Q4 2025

Type / Class
Equity / Ordinary shares, par value $0.0001 per share
Symbol
ONC on Nasdaq
Shares outstanding
1,385,160,313
Price per share
$303.82
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
32,948,887
Total reported value
$11,222,689,485
% of total 13F portfolios
0%
Share change
-1,441,353
Value change
-$347,137,551
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
259
Price from insider filings
$17.85
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
HHLR ADVISORS, LTD. 4.9% -26% $16,788,174,431 -$5,939,951,540 68,551,141 -26% HHLR Advisors, Ltd. 09 May 2025
As of 30 Sep 2025, BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC) has 259 institutional shareholders filing 13F forms. They hold 32,948,887 shares. of 1,385,160,313 outstanding shares (2.4%) .

Institutional Holders of BeOne Medicines Ltd. - Ordinary shares, par value $0.0001 per share (ONC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 7,222 $2,194,427 -$531,969 30,381.54% 5
2025 Q3 32,948,887 $11,222,689,485 -$347,137,551 34,070% 259
2025 Q2 34,445,503 $8,338,029,358 -$2,097,913,474 24,207% 240
2025 Q1 42,522,929 $11,571,304,178 -$300,776,021 27,217% 260
2024 Q4 43,668,178 $8,065,581,343 -$576,365,574 18,471% 222
2024 Q3 46,519,526 $10,440,141,817 -$116,771,313 22,451% 221
2024 Q2 46,804,066 $6,679,478,929 +$49,458,709 14,267% 195
2024 Q1 46,433,670 $7,261,664,670 +$228,390,098 15,639% 198
2023 Q4 44,965,141 $8,109,589,388 -$358,939,167 18,036% 201
2023 Q3 46,934,356 $8,443,617,070 -$8,576,628 17,987% 195
2023 Q2 47,044,110 $8,388,424,595 -$134,114,517 17,830% 200
2023 Q1 47,729,619 $10,288,729,347 -$365,549,782 21,553% 214
2022 Q4 49,411,792 $10,871,665,562 -$822,129,900 21,994% 206
2022 Q3 53,491,519 $7,213,600,064 -$18,667,417 13,482% 204
2022 Q2 53,542,991 $8,666,746,485 -$222,094,321 16,185.01% 217
2022 Q1 54,923,857 $10,369,831,154 -$143,839,726 18,860% 228
2021 Q4 55,475,829 $15,026,076,469 -$242,691,110 27,093% 247
2021 Q3 56,111,399 $20,367,209,544 +$187,897,220 36,300% 242
2021 Q2 55,478,557 $19,043,602,189 -$143,508,273 34,318.94% 259
2021 Q1 55,905,428 $19,451,416,879 +$655,221,281 34,807.7% 241
2020 Q4 54,296,531 $14,026,755,839 -$183,663,940 25,838.87% 234
2020 Q3 54,822,916 $15,700,067,419 +$1,338,448,467 28,643.88% 238
2020 Q2 50,121,058 $9,441,745,077 +$213,639,854 18,840% 209
2020 Q1 48,964,204 $6,027,968,489 -$8,363,206 12,311% 205
2019 Q4 48,934,325 $8,110,832,589 -$138,704,780 16,576% 217
2019 Q3 49,991,082 $6,121,591,847 +$324,001,095 12,245.97% 192
2019 Q2 49,119,839 $6,088,356,127 +$19,061,884 12,395% 196
2019 Q1 46,975,583 $6,199,612,280 +$70,636,203 13,199.99% 193
2018 Q4 47,454,252 $6,654,826,169 -$438,071,948 14,025.99% 188
2018 Q3 45,496,681 $7,835,602,804 +$598,946,530 17,221.98% 142
2018 Q2 42,212,313 $6,489,342,702 +$892,872,904 15,373% 128
2018 Q1 36,449,398 $6,123,436,880 +$1,501,911,684 16,800% 122
2017 Q4 27,567,001 $2,693,889,000 +$229,200,708 9,772.02% 93
2017 Q3 25,192,357 $2,606,391,144 +$502,359,860 10,346% 81
2017 Q2 20,400,002 $917,998,000 +$131,190,803 4,499.96% 57
2017 Q1 17,607,585 $644,614,000 +$43,545,126 3,661% 54
2016 Q4 16,604,419 $504,116,000 +$195,354,542 3,035.99% 54
2016 Q3 10,161,007 $313,122,000 +$58,302,863 3,081.08% 38
2016 Q2 8,275,591 $241,301,000 +$16,647,965 2,980% 39
2016 Q1 7,721,859 $221,022,000 +$221,022,000 2,931.1% 40